CytoDyn Raises over $12 Million in New Capital from Private and Public Warrant Offers in the Last Five Weeks with Minimum Dilution Jun 14, 2019 6:00am EDT
CytoDyn to Present Pivotal Data at ASM Microbe 2019 Demonstrating Efficacy and Safety of Leronlimab (PRO 140) in HIV Patients with Multiple ARV Class Resistance Jun 13, 2019 6:00am EDT
CytoDyn and FDA Will Meet to Potentially Finalize Protocol for Pivotal Monotherapy Trial for Leronlimab Jun 07, 2019 6:00am EDT
CytoDyn to Present at the 9th Annual LD Micro Invitational Conference on June 5 May 30, 2019 6:00am EDT
CytoDyn Strengthens Management Team with Key Additions in Business Development and Quality Regulatory Compliance as it Advances Commercialization Plan for Leronlimab May 14, 2019 6:00am EDT
CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with The Cleveland Clinic’s Dr. Daniel J. Lindner, M.D., Ph.D. May 13, 2019 6:00am EDT
CytoDyn Provides Updated Pre-Clinical Data Showing Leronlimab (PRO 140) Continues to Suppress Breast Cancer Metastatic Burden >98% Compared with Untreated Animals May 08, 2019 9:08am EDT
CytoDyn’s Monotherapy Trial with Leronlimab (PRO 140) Reaches its Ultimate Goals May 06, 2019 6:00am EDT
